Valorisation of the efficacy of 9-cis beta-carotene in treating atherosclerosis, psoriasis, and inhibiting atherogenesis and retinitis pigmentosa is becoming increasingly urgent, but supplies of 9-cis beta-carotene are scarce and this compound is difficult to synthesise chemically, unlike the much more common all-trans form. Innovative products, processes and services in an algal biorefinery that rely on renewable biological resources instead of fossil fuel alternatives offer the potential to lower the energy costs of traditional chemical processes and reduce carbon emissions, water usage and waste. In 2013, the European Commission supported development of 4 microalgal biorefinery projects to assess the potential for innovative approaches to tackle the major challenges intrinsic to the development of the algae biorefineries. One of these was the D-Factory (KBBE.2013.3.2-02) which sought to evaluate requirements for sustainable, industrial-scale production of Dunaliella salina and extraction of its carotenoids, especially 9-cis beta-carotene in a CO₂ microalgae biorefinery. Here we present findings of the D-Factory project and propose a way forward for industrial-scale production of 9-cis beta-carotene using biotechnology based on Dunaliella salina biomass. Cultivation improvements are able to deliver more than double the current levels of productivity, with increased sustainability, whilst the use of natural hyper-accumulating carotenogenic strains combined with the use of red light to boost production of the beta-carotene pathway, will increase the relative concentration of 9-cis beta-carotene in extracts of carotenoids with consequent improvements in downstream processing. These developments pave the way for acquiring data for a Medicine Licence and prepare the market for entry of novel 9-cis beta-carotene products.

评估9-顺式β-胡萝卜素治疗动脉粥样硬化，牛皮癣以及抑制动脉粥样硬化和色素性视网膜炎的功效正变得越来越紧迫，但9-顺式β-胡萝卜素的供应却很少，而且该化合物很难化学合成。更常见的全反式形成。依靠可再生生物资源而非化石燃料替代品的藻类生物精炼厂中的创新产品，工艺和服务，有可能降低传统化学工艺的能源成本并减少碳排放，水的使用和浪费。2013年，欧盟委员会支持了4个微藻类生物精炼厂项目的开发，以评估创新方法应对藻类生物精炼厂发展所固有的主要挑战的潜力。其中之一是D工厂（KBBE.2013.3.2-02），该工厂试图评估可持续工业规模生产杜氏盐藻和提取其类胡萝卜素，尤其是在CO _2中的9-顺式β-胡萝卜素的要求。微藻生物精炼厂。在这里，我们介绍D-Factory项目的发现，并提出使用基于杜氏盐藻生物量的生物技术工业规模生产9-顺式β-胡萝卜素的方法。改良耕作方法可以使目前的生产力水平提高一倍以上，并具有更大的可持续性，同时使用天然的高积累类胡萝卜素菌株和红光组合来提高β-胡萝卜素途径的产量，将增加相对类胡萝卜素提取物中9-顺式β-胡萝卜素的浓度，从而改善了下游加工过程。这些发展为获取药品许可的数据铺平了道路，并为新型小说的进入市场做准备。9-顺式β-胡萝卜素产品。